Spots Global Cancer Trial Database for S9005 Mifepristone in Meningioma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: S9005 Mifepristone in Meningioma
Official Title: Double Blind Randomized Trial of the Anti-Progestational Agent Mifepristone In The Treatment of Unresectable Meningioma
Study ID: NCT03015701
Conditions
Study Description
Brief Summary: To compare daily oral mifepristone vs placebo with respect to time to treatment failure in patients with unresectable meningioma.
Detailed Description: To compare daily oral mifepristone vs placebo with respect to time to treatment failure in patients with unresectable meningioma and to address issues of safety in this patient population.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Contact Details
Name: Charles Blanke, MD
Affiliation: Oregon Health and Sciences University
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
